董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Willy Simon | 男 | Senior Non Executive Director | 74 | 5.00万美元 | 未持股 | 2026-01-05 |
| Gabriele Cerrone | 男 | Non Executive Chairman | 54 | 44.50万美元 | 未持股 | 2026-01-05 |
| John Brancaccio | 男 | Non Executive Director | 78 | 8.60万美元 | 未持股 | 2026-01-05 |
| Bernard Denoyer | 男 | Non Executive Director | 78 | 5.10万美元 | 未持股 | 2026-01-05 |
| Robert J. Dempsey | 男 | Chief Executive Officer and Executive Director | -- | 未披露 | 未持股 | 2026-01-05 |
| Gary S. Jacob | 男 | Chief Development Officer and Executive Director | 78 | 131.00万美元 | 未持股 | 2026-01-05 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Raj Patil | 男 | Chief Scientific Officer | 68 | 未披露 | 未持股 | 2026-01-05 |
| Keeren Shah | 女 | Chief Financial Officer | 50 | 未披露 | 未持股 | 2026-01-05 |
| Robert J. Dempsey | 男 | Chief Executive Officer and Executive Director | -- | 未披露 | 未持股 | 2026-01-05 |
| Gary S. Jacob | 男 | Chief Development Officer and Executive Director | 78 | 131.00万美元 | 未持股 | 2026-01-05 |
董事简历
中英对照 | 中文 | 英文- Willy Simon
-
Willy Simon自2015年11月起担任公司非执行董事。Simon先生从2007年8月开始担任Bever Holding B.V.的非执行主席，这是一家专注于房地产开发的荷兰上市上市公司。Simon先生从2000年1月到2002年7月担任Fortis Investment Management的首席执行官。Simon先生从1975年8月到1983年12月在KredietBank N.V.工作，从1984年1月到1996年12月在Citibank London工作，然后从1997年1月到1999年12月担任Generale Bank NL的董事会执行成员。从2004年7月到2012年4月，他曾担任Redi&Partners公司（基金的基金）的非执行董事。Simon从2012年4月到2014年4月担任AIM-Traded Velox3plc（前身为24/7Gaming Group Holdings plc，一家专注于为移动游戏行业发布和开发游戏软件的公司）董事长。Simon从2003年12月到2111年9月担任PlayLogic Entertainment Inc.（一家纳斯达克上市公司，专注于开发、出版和销售交互式软件游戏）董事。Simon从202年9月到2004年12月担任Bank Oyens&Van Eeghen董事长。Simon先生拥有卢万大学（University of Louvain）的法律学位和斯特拉斯堡高等研究学院（Institut des Hautes Etudes Europe&233；Ennes）的欧洲法律和经济学研究生学位。
Willy Simon,has been a director of company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences Limited, AccuStem Sciences Inc and Actavia Lifesciences, Inc. - Willy Simon自2015年11月起担任公司非执行董事。Simon先生从2007年8月开始担任Bever Holding B.V.的非执行主席，这是一家专注于房地产开发的荷兰上市上市公司。Simon先生从2000年1月到2002年7月担任Fortis Investment Management的首席执行官。Simon先生从1975年8月到1983年12月在KredietBank N.V.工作，从1984年1月到1996年12月在Citibank London工作，然后从1997年1月到1999年12月担任Generale Bank NL的董事会执行成员。从2004年7月到2012年4月，他曾担任Redi&Partners公司（基金的基金）的非执行董事。Simon从2012年4月到2014年4月担任AIM-Traded Velox3plc（前身为24/7Gaming Group Holdings plc，一家专注于为移动游戏行业发布和开发游戏软件的公司）董事长。Simon从2003年12月到2111年9月担任PlayLogic Entertainment Inc.（一家纳斯达克上市公司，专注于开发、出版和销售交互式软件游戏）董事。Simon从202年9月到2004年12月担任Bank Oyens&Van Eeghen董事长。Simon先生拥有卢万大学（University of Louvain）的法律学位和斯特拉斯堡高等研究学院（Institut des Hautes Etudes Europe&233；Ennes）的欧洲法律和经济学研究生学位。
- Willy Simon,has been a director of company since November 2015. He is a banker and worked at Kredietbank N.V. and Citibank London before serving as an executive member of the Board of Generale Bank NL from 1997 to 1999 and as the chief executive of Fortis Investment Management from 1999 to 2002. He acted as chairman of Bank Oyens & van Eeghen from 2002 to 2004. He was chairman of AIM-traded Velox3 plc (formerly 24/7 Gaming Group Holdings plc) until 2014 and had been a director of Playlogic Entertainment Inc., a NASDAQ OTC listed company. Willy Simon has been the chairman of Bever Holdings, a company listed in Amsterdam, since 2006 and Chairman of Ducat Maritime since 2015. He is also a non-executive director of Tiziana Life Sciences Limited, AccuStem Sciences Inc and Actavia Lifesciences, Inc.
- Gabriele Cerrone
-
Gabriele Cerrone自2021年1月起担任我们公司的非执行主席。Cerrone先生是Tiziana Life Sciences Limited的创始人，自2014年4月起担任其执行主席。Cerrone先生在肿瘤学、传染病和分子诊断领域创立了10家生物技术公司，其中7家公司在纳斯达克上市，2家在伦敦的Main Market和AIM Market上市。Cerrone先生共同创立了肿瘤公司Cardiff Oncology, Inc.，并担任其联席主席；他是Synergy Pharmaceuticals，Inc.和Callisto Pharmaceuticals，Inc.的联合创始人并担任董事长，并且是SIGA技术公司的董事并领导其重组，Cerrone先生还共同创立了Fermavir Pharmaceuticals，Inc.，并担任董事会主席，直至该公司于2007年9月与Inhibitex，Inc.合并。Cerrone先生一直担任Inhibitex，Inc.的董事，直至2012年将Inhibitex，Inc.以25亿美元的价格出售给百时美施贵宝公司。Cerrone先生是在纳斯达克上市的Tiziana Life Sciences Limited的执行主席和创始人，该公司是一家专注于肿瘤治疗的公司；Rasna Therapeutics Inc.的联合创始人，该公司专注于白血病治疗的开发；Hepion Pharmaceuticals, Inc.的联合创始人；Gensignia Life Sciences，Inc.的执行主席兼联合创始人，一家专注于使用microRNA技术的肿瘤学的分子诊断公司；Accustem Sciences Limited的非执行主席兼创始人；Biovitas Capital Ltd.创始人Cerrone先生毕业于纽约大学斯特恩商学院，获得工商管理硕士学位。
Gabriele Cerrone,has been the Non-Executive Chairman of Okyo Pharma Limited since January 2021. Mr. Cerrone is the Founder of Tiziana Life Sciences Limited and has been its Executive Chairman since April 2014. Mr. Cerrone has founded 10 biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has listed seven of these companies on NASDAQ, and two to the Main Market and AIM Market in London. Mr. Cerrone co-founded Cardiff Oncology, Inc., an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc. and was a Director of and led the restructuring of Siga Technologies, Inc. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012. Mr. Cerrone is the Executive Chairman and Founder of NASDAQ-listed Tiziana Life Sciences Limited, an oncology focused therapeutics company; Co-Founder of Actavia Therapeutics Inc., a company focused on the development of therapeutics for leukaemias; Co-Founder of Hepion Pharmaceuticals, Inc.; Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology Okyo Pharma Limited ing microRNA technology; Non-Executive Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital Ltd. Mr. Cerrone graduated from New York University's Stern School of Business with a master's degree in business administration (MBA). - Gabriele Cerrone自2021年1月起担任我们公司的非执行主席。Cerrone先生是Tiziana Life Sciences Limited的创始人，自2014年4月起担任其执行主席。Cerrone先生在肿瘤学、传染病和分子诊断领域创立了10家生物技术公司，其中7家公司在纳斯达克上市，2家在伦敦的Main Market和AIM Market上市。Cerrone先生共同创立了肿瘤公司Cardiff Oncology, Inc.，并担任其联席主席；他是Synergy Pharmaceuticals，Inc.和Callisto Pharmaceuticals，Inc.的联合创始人并担任董事长，并且是SIGA技术公司的董事并领导其重组，Cerrone先生还共同创立了Fermavir Pharmaceuticals，Inc.，并担任董事会主席，直至该公司于2007年9月与Inhibitex，Inc.合并。Cerrone先生一直担任Inhibitex，Inc.的董事，直至2012年将Inhibitex，Inc.以25亿美元的价格出售给百时美施贵宝公司。Cerrone先生是在纳斯达克上市的Tiziana Life Sciences Limited的执行主席和创始人，该公司是一家专注于肿瘤治疗的公司；Rasna Therapeutics Inc.的联合创始人，该公司专注于白血病治疗的开发；Hepion Pharmaceuticals, Inc.的联合创始人；Gensignia Life Sciences，Inc.的执行主席兼联合创始人，一家专注于使用microRNA技术的肿瘤学的分子诊断公司；Accustem Sciences Limited的非执行主席兼创始人；Biovitas Capital Ltd.创始人Cerrone先生毕业于纽约大学斯特恩商学院，获得工商管理硕士学位。
- Gabriele Cerrone,has been the Non-Executive Chairman of Okyo Pharma Limited since January 2021. Mr. Cerrone is the Founder of Tiziana Life Sciences Limited and has been its Executive Chairman since April 2014. Mr. Cerrone has founded 10 biotechnology companies in oncology, infectious diseases and molecular diagnostics, and has listed seven of these companies on NASDAQ, and two to the Main Market and AIM Market in London. Mr. Cerrone co-founded Cardiff Oncology, Inc., an oncology company and served as its Co-Chairman; he was a co-founder and served as Chairman of both Synergy Pharmaceuticals, Inc. and Callisto Pharmaceuticals, Inc. and was a Director of and led the restructuring of Siga Technologies, Inc. Mr. Cerrone also co-founded FermaVir Pharmaceuticals, Inc. and served as Chairman of the Board until its merger in September 2007 with Inhibitex, Inc. Mr. Cerrone served as a director of Inhibitex, Inc. until its US$2.5bn sale to Bristol Myers Squibb Co in 2012. Mr. Cerrone is the Executive Chairman and Founder of NASDAQ-listed Tiziana Life Sciences Limited, an oncology focused therapeutics company; Co-Founder of Actavia Therapeutics Inc., a company focused on the development of therapeutics for leukaemias; Co-Founder of Hepion Pharmaceuticals, Inc.; Executive Chairman and Co-Founder of Gensignia Life Sciences, Inc., a molecular diagnostics company focused on oncology Okyo Pharma Limited ing microRNA technology; Non-Executive Chairman and Founder of Accustem Sciences Limited; and founder of BioVitas Capital Ltd. Mr. Cerrone graduated from New York University's Stern School of Business with a master's degree in business administration (MBA).
- John Brancaccio
-
John Brancaccio，退休注册会计师，自2020年6月起担任本公司董事。从2004年4月到2017年5月，Brancaccio先生担任Accelerated Technologies，Inc.的首席财务官，该公司是医疗器械公司的孵化器。Brancaccio先生自2004年4月起担任Callisto Pharmaceuticals，Inc.的董事，直至2013年1月与Synergy Pharmaceuticals，Inc.合并，并自2004年4月起担任Tamir Biotechnology，Inc.（前身为Alfacell Corporation）的董事以及董事Hepion Pharmaceuticals，Inc.自2013年12月起Rasna Therapeutics，Inc.自2016年9月起Cardiff Oncology，Inc.自2005年12月起和Tiziana Life Sciences Limited自2020年7月起。Brancaccio先生于2008年7月至2019年4月担任Synergy的董事。
John Brancaccio,a retired CPA, has served as a director of company since June 2020. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio has been a director of Tiziana Life Sciences Limited since July 2020. Mr. Brancaccio served as a director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) from April 2004 until May 2020, as well as a director of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019. He is also a non-executive director of AccuStem Sciences Inc and Actavia Therapeutics Inc. Mr. Brancaccio is a past director of Cardiff Oncology, Inc.. - John Brancaccio，退休注册会计师，自2020年6月起担任本公司董事。从2004年4月到2017年5月，Brancaccio先生担任Accelerated Technologies，Inc.的首席财务官，该公司是医疗器械公司的孵化器。Brancaccio先生自2004年4月起担任Callisto Pharmaceuticals，Inc.的董事，直至2013年1月与Synergy Pharmaceuticals，Inc.合并，并自2004年4月起担任Tamir Biotechnology，Inc.（前身为Alfacell Corporation）的董事以及董事Hepion Pharmaceuticals，Inc.自2013年12月起Rasna Therapeutics，Inc.自2016年9月起Cardiff Oncology，Inc.自2005年12月起和Tiziana Life Sciences Limited自2020年7月起。Brancaccio先生于2008年7月至2019年4月担任Synergy的董事。
- John Brancaccio,a retired CPA, has served as a director of company since June 2020. From April 2004 until May 2017, Mr. Brancaccio was the Chief Financial Officer of Accelerated Technologies, Inc., an incubator for medical device companies. Mr. Brancaccio has been a director of Tiziana Life Sciences Limited since July 2020. Mr. Brancaccio served as a director of Callisto Pharmaceuticals, Inc. from April 2004 until its merger with Synergy Pharmaceuticals, Inc. in January 2013 and was a director of Tamir Biotechnology, Inc. (formerly Alfacell Corporation) from April 2004 until May 2020, as well as a director of Hepion Pharmaceuticals, Inc. from December 2013 until June 2025. Mr. Brancaccio served as a director of Synergy from July 2008 until April 2019. He is also a non-executive director of AccuStem Sciences Inc and Actavia Therapeutics Inc. Mr. Brancaccio is a past director of Cardiff Oncology, Inc..
- Bernard Denoyer
-
Bernard Denoyer自2021年12月起担任我们公司的董事。Denoyer先生自2008年7月起担任Synergy Pharmaceuticals，Inc的高级副总裁、财务和秘书，直至2017年6月退休。2004年至2013年1月，Denoyer先生同时担任Synergy的前母公司Callisto Pharmaceuticals，Inc.的首席财务官。2000年10月至2003年12月，Denoyer先生担任独立顾问。在此之前，Denoyer先生曾担任Meta Group，Inc.的副总裁兼高级管理人员。他目前在两家非营利组织St. Edmunds Retreat，Inc.和Midwestern Connecticut Council on Alcoholism，Inc.的董事会任职。
Bernard Denoyer,a retired CPA, has served as a director of company since December 2021. Mr. Denoyer served as Senior Vice President, Finance and Secretary of Synergy Pharmaceuticals, Inc, from July 2008 until his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently served as Principal Financial Officer of Synergy's former parent company, Callisto Pharmaceuticals, Inc., until its merger with Synergy Pharmaceuticals, Inc. From October 2000 to December 2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc., between June 1994 and October 2000. - Bernard Denoyer自2021年12月起担任我们公司的董事。Denoyer先生自2008年7月起担任Synergy Pharmaceuticals，Inc的高级副总裁、财务和秘书，直至2017年6月退休。2004年至2013年1月，Denoyer先生同时担任Synergy的前母公司Callisto Pharmaceuticals，Inc.的首席财务官。2000年10月至2003年12月，Denoyer先生担任独立顾问。在此之前，Denoyer先生曾担任Meta Group，Inc.的副总裁兼高级管理人员。他目前在两家非营利组织St. Edmunds Retreat，Inc.和Midwestern Connecticut Council on Alcoholism，Inc.的董事会任职。
- Bernard Denoyer,a retired CPA, has served as a director of company since December 2021. Mr. Denoyer served as Senior Vice President, Finance and Secretary of Synergy Pharmaceuticals, Inc, from July 2008 until his retirement in June 2017. Between 2004 and January 2013 Mr. Denoyer concurrently served as Principal Financial Officer of Synergy's former parent company, Callisto Pharmaceuticals, Inc., until its merger with Synergy Pharmaceuticals, Inc. From October 2000 to December 2003, Mr. Denoyer was an independent consultant. Prior to this, Mr. Denoyer served as Chief Financial Officer and Senior Vice President of META Group, Inc., between June 1994 and October 2000.
- Robert J. Dempsey
-
Robert J. Dempsey，曾在Shire担任集团副总裁兼全球眼科主管，在被武田收购之前，他领导了Xiidra的剥离工作（lifitegrast眼科解决方案）5%，这是过去二十年中仅有的三笔预付款超过10亿美元的眼科交易之一。Xiidra的出售2019年向诺华支付的款项包括34亿美元的预付款和高达19亿美元的潜在里程碑付款。希德拉是首个获得FDA批准的针对干眼症体征和症状的疗法，并随后成为全球最畅销的品牌干眼症疗法之一。Dempsey先生设计并领导了Xiidra的成功发布并在眼表疾病适应症方面带来深厚的战略和商业专业知识，包括Restasis的直接管理责任和商业监督（环孢素眼用乳剂）0.05%。他在眼保健界的专业人脉广泛而成熟，反映出他作为CEO和独立董事在多家眼科公司的服务。
Robert J. Dempsey,previously served as Group Vice President and Head of Global Ophthalmology at Shire, prior to its acquisition by Takeda, where he led the divestiture of Xiidra (lifitegrast ophthalmic solution) 5%, which was one of only three ophthalmology deals in the past twenty years with more than $1 billion upfront. The sale of Xiidra to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments. Xiidra was the first FDA-approved therapy indicated for both the signs and symptoms of dry eye disease and went on to become one of the top-selling branded dry eye treatments globally. Mr. Dempsey architected and led the successful launch of Xiidra and has deep strategic and commercial expertise across ocular surface disease indications, including direct management responsibility and commercial oversight for Restasis (cyclosporine ophthalmic emulsion) 0.05%. His professional network in the eye care community is broad and well-established, reflecting his service as a CEO and independent director across multiple ophthalmic companies. - Robert J. Dempsey，曾在Shire担任集团副总裁兼全球眼科主管，在被武田收购之前，他领导了Xiidra的剥离工作（lifitegrast眼科解决方案）5%，这是过去二十年中仅有的三笔预付款超过10亿美元的眼科交易之一。Xiidra的出售2019年向诺华支付的款项包括34亿美元的预付款和高达19亿美元的潜在里程碑付款。希德拉是首个获得FDA批准的针对干眼症体征和症状的疗法，并随后成为全球最畅销的品牌干眼症疗法之一。Dempsey先生设计并领导了Xiidra的成功发布并在眼表疾病适应症方面带来深厚的战略和商业专业知识，包括Restasis的直接管理责任和商业监督（环孢素眼用乳剂）0.05%。他在眼保健界的专业人脉广泛而成熟，反映出他作为CEO和独立董事在多家眼科公司的服务。
- Robert J. Dempsey,previously served as Group Vice President and Head of Global Ophthalmology at Shire, prior to its acquisition by Takeda, where he led the divestiture of Xiidra (lifitegrast ophthalmic solution) 5%, which was one of only three ophthalmology deals in the past twenty years with more than $1 billion upfront. The sale of Xiidra to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments. Xiidra was the first FDA-approved therapy indicated for both the signs and symptoms of dry eye disease and went on to become one of the top-selling branded dry eye treatments globally. Mr. Dempsey architected and led the successful launch of Xiidra and has deep strategic and commercial expertise across ocular surface disease indications, including direct management responsibility and commercial oversight for Restasis (cyclosporine ophthalmic emulsion) 0.05%. His professional network in the eye care community is broad and well-established, reflecting his service as a CEO and independent director across multiple ophthalmic companies.
- Gary S. Jacob
-
Gary S. Jacob，自2021年1月起担任Okyo Pharma Limited首席执行官兼董事。2018年11月至2020年3月，Jacob博士担任澳大利亚微生物组生物制药公司Immuron Limited的首席执行官。从2008年7月到2017年12月，Jacob博士担任生物制药公司Synergy Pharmaceuticals Inc.的总裁兼首席执行官，并于2008年7月至2018年11月担任多个职位，并于2013年9月至2018年11月担任Synergy Pharmaceuticals Inc.的董事长。2018年12月12日，Synergy Pharmaceuticals Inc.根据美国《破产法》第11章提交了一份救济申请。自2014年3月19日起，Jacob博士一直担任生物技术公司Hepion Pharmaceuticals, Inc.的董事会主席，更早前于2013年5月15日至2014年3月19日担任首席执行官。Jacob博士于2003年5月至2013年1月期间担任Callisto Pharmaceuticals，Inc.的首席执行官，并于2004年10月至2013年1月期间担任董事。Jacob博士还担任Rasna Therapeutics，Inc.的董事，并且是Cardiff Oncology, Inc.的前任董事。Jacob博士在制药和生物技术行业拥有超过35年的经验，跨越多个学科，包括研发、运营和业务发展。在1999年之前，Jacob博士曾担任Monsanto科学研究员，专门研究糖生物学领域。1997年至1998年，Jacob博士在Monsanto公司担任企业科学与技术部门功能基因组学主任。Jacob博士还曾于1990年至1997年担任G.D. Searle Pharmaceuticals Inc的糖生物学总监。在1986年至1990年期间，他担任英国牛津大学G.D. Searle糖生物学小组的经理。
Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. From March 19, 2014 until February 2024, Dr. Jacob was the Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Actavia Lifesciences, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England. - Gary S. Jacob，自2021年1月起担任Okyo Pharma Limited首席执行官兼董事。2018年11月至2020年3月，Jacob博士担任澳大利亚微生物组生物制药公司Immuron Limited的首席执行官。从2008年7月到2017年12月，Jacob博士担任生物制药公司Synergy Pharmaceuticals Inc.的总裁兼首席执行官，并于2008年7月至2018年11月担任多个职位，并于2013年9月至2018年11月担任Synergy Pharmaceuticals Inc.的董事长。2018年12月12日，Synergy Pharmaceuticals Inc.根据美国《破产法》第11章提交了一份救济申请。自2014年3月19日起，Jacob博士一直担任生物技术公司Hepion Pharmaceuticals, Inc.的董事会主席，更早前于2013年5月15日至2014年3月19日担任首席执行官。Jacob博士于2003年5月至2013年1月期间担任Callisto Pharmaceuticals，Inc.的首席执行官，并于2004年10月至2013年1月期间担任董事。Jacob博士还担任Rasna Therapeutics，Inc.的董事，并且是Cardiff Oncology, Inc.的前任董事。Jacob博士在制药和生物技术行业拥有超过35年的经验，跨越多个学科，包括研发、运营和业务发展。在1999年之前，Jacob博士曾担任Monsanto科学研究员，专门研究糖生物学领域。1997年至1998年，Jacob博士在Monsanto公司担任企业科学与技术部门功能基因组学主任。Jacob博士还曾于1990年至1997年担任G.D. Searle Pharmaceuticals Inc的糖生物学总监。在1986年至1990年期间，他担任英国牛津大学G.D. Searle糖生物学小组的经理。
- Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. From March 19, 2014 until February 2024, Dr. Jacob was the Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Actavia Lifesciences, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.
高管简历
中英对照 | 中文 | 英文- Raj Patil
Raj Patil自2021年3月起担任我们公司的首席科学官。Patil博士拥有超过15年的眼科药物开发经验，包括研发、运营和业务开发。Patil博士之前曾在ORA工作，担任研发副总裁，负责推动ORA研发研究所的所有前后节眼部研究。从2013年到2018年，Patil博士在Iveena Delivery Systems担任高级眼科输送系统副总裁。Patil博士在Iveena的任期包括在新加坡休假两年，在那里他担任杜克大学/新加坡国立大学医学院眼科副教授和新加坡眼科研究所首席研究员。从2004年到2013年，Patil博士还在爱尔康/诺华生物医学研究所担任过多个领导职务，包括研究副主任和分子药理学负责人-青光眼和视网膜研究。2004年之前，Patil博士于2001年至2004年在奥马哈的内布拉斯加大学医学中心担任眼科、细胞生物学和遗传学副教授，并在圣路易斯华盛顿大学担任眼科、分子生物学和药理学助理教授从1992年到2000年。Patil博士在印度浦那大学国家化学实验室获得生物化学博士学位，并在密歇根州安娜堡的密歇根大学完成了生物化学和分子生物学博士后培训。他是预防失明研究基金会的Olga Keith Wiess特别学者奖和NIH导演的新创新者奖的获得者。Patil博士撰写了50多篇同行评审的研究文章，担任众多期刊的审稿人和编辑委员会成员，并经常受邀在学术和行业活动中发表演讲。
Raj Patil,has served as Chief Scientific Officer of company since March 2021. Dr. Patil has over 15 years of ophthalmic drug development experience, including research & development, operations and business development. Dr. Patil previously worked with Ora, as Vice President of Research & Development, where he was responsible for driving all anterior and posterior segment ocular research of Ora's R&D Institute. From 2013 until 2018, Dr. Patil worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. Dr. Patil's tenure at iVeena included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School, and Principal Investigator at Singapore Eye Research Institute. From 2004 until 2013, Dr. Patil also held a number of leadership roles at Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology - glaucoma and retina research. Prior to 2004, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology & Genetics at the University of Nebraska Medical Centre in Omaha from 2001 until 2004, and as an Assistant Professor of Ophthalmology, Molecular Biology & Pharmacology at Washington University in St. Louis from 1992 until 2000. Dr. Patil received his PhD in Biochemistry from National Chemical Laboratory/University of Pune, India, and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor, MI. He is the recipient of the Olga Keith Wiess Special Scholar Award from the Research to Prevent Blindness Foundation, and NIH Director's New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles, serves as reviewer and editorial board member for numerous journals, and is frequently invited to lecture at academic and industry events.- Raj Patil自2021年3月起担任我们公司的首席科学官。Patil博士拥有超过15年的眼科药物开发经验，包括研发、运营和业务开发。Patil博士之前曾在ORA工作，担任研发副总裁，负责推动ORA研发研究所的所有前后节眼部研究。从2013年到2018年，Patil博士在Iveena Delivery Systems担任高级眼科输送系统副总裁。Patil博士在Iveena的任期包括在新加坡休假两年，在那里他担任杜克大学/新加坡国立大学医学院眼科副教授和新加坡眼科研究所首席研究员。从2004年到2013年，Patil博士还在爱尔康/诺华生物医学研究所担任过多个领导职务，包括研究副主任和分子药理学负责人-青光眼和视网膜研究。2004年之前，Patil博士于2001年至2004年在奥马哈的内布拉斯加大学医学中心担任眼科、细胞生物学和遗传学副教授，并在圣路易斯华盛顿大学担任眼科、分子生物学和药理学助理教授从1992年到2000年。Patil博士在印度浦那大学国家化学实验室获得生物化学博士学位，并在密歇根州安娜堡的密歇根大学完成了生物化学和分子生物学博士后培训。他是预防失明研究基金会的Olga Keith Wiess特别学者奖和NIH导演的新创新者奖的获得者。Patil博士撰写了50多篇同行评审的研究文章，担任众多期刊的审稿人和编辑委员会成员，并经常受邀在学术和行业活动中发表演讲。
- Raj Patil,has served as Chief Scientific Officer of company since March 2021. Dr. Patil has over 15 years of ophthalmic drug development experience, including research & development, operations and business development. Dr. Patil previously worked with Ora, as Vice President of Research & Development, where he was responsible for driving all anterior and posterior segment ocular research of Ora's R&D Institute. From 2013 until 2018, Dr. Patil worked at iVeena Delivery Systems as Vice President of Advanced Ocular Delivery Systems. Dr. Patil's tenure at iVeena included a two-year sabbatical in Singapore, where he served as an Associate Professor of Ophthalmology at DUKE/NUS Medical School, and Principal Investigator at Singapore Eye Research Institute. From 2004 until 2013, Dr. Patil also held a number of leadership roles at Alcon/Novartis Institute of Biomedical Research, including Associate Director of Research and Head of Molecular Pharmacology - glaucoma and retina research. Prior to 2004, Dr. Patil served as an Associate Professor of Ophthalmology, Cell Biology & Genetics at the University of Nebraska Medical Centre in Omaha from 2001 until 2004, and as an Assistant Professor of Ophthalmology, Molecular Biology & Pharmacology at Washington University in St. Louis from 1992 until 2000. Dr. Patil received his PhD in Biochemistry from National Chemical Laboratory/University of Pune, India, and completed his postdoctoral training in Biochemistry and Molecular Biology at the University of Michigan, Ann Arbor, MI. He is the recipient of the Olga Keith Wiess Special Scholar Award from the Research to Prevent Blindness Foundation, and NIH Director's New Innovator Award. Dr. Patil has authored over 50 peer-reviewed research articles, serves as reviewer and editorial board member for numerous journals, and is frequently invited to lecture at academic and industry events.
- Keeren Shah
Keeren Shah自2020年8月起担任我们的首席财务官。Shah女士目前还担任Tiziana Life Sciences Limited、Accustem Sciences Limited和Rasna Therapeutics Inc.的财务总监，此前曾于2016年6月至2020年7月担任所有业务的集团财务总监。在加入我们之前，Shah女士在Visa，Inc.工作了10年，担任其财务团队的高级领导，负责关键的财务总监活动、财务规划和分析，和核心流程，以及领导和参与关键的转型计划和Visa Inc.的首次公开募股。在加入Visa之前，Shah女士还在其他领先公司担任过各种财务职位，包括Arthur Andersen和BBC Worldwide。她拥有经济学荣誉文学学士学位，并且是英国特许管理会计师协会的会员。
Keeren Shah,has served as Chief Financial Officer since August 2020. Ms. Shah currently also serves as the Chief Operating and Financial Officer of Tiziana Life Sciences Limited, Accustem Sciences Inc and Actavia Lifesciences, Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining Okyo Pharma Limited , Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as well as leading and participating in key transformation programs and Visa Inc.'s initial public offering. Before joining Visa, Ms. Shah also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of Arts with Honors in Economics and is a member of the Chartered Institute of Management Accountants.- Keeren Shah自2020年8月起担任我们的首席财务官。Shah女士目前还担任Tiziana Life Sciences Limited、Accustem Sciences Limited和Rasna Therapeutics Inc.的财务总监，此前曾于2016年6月至2020年7月担任所有业务的集团财务总监。在加入我们之前，Shah女士在Visa，Inc.工作了10年，担任其财务团队的高级领导，负责关键的财务总监活动、财务规划和分析，和核心流程，以及领导和参与关键的转型计划和Visa Inc.的首次公开募股。在加入Visa之前，Shah女士还在其他领先公司担任过各种财务职位，包括Arthur Andersen和BBC Worldwide。她拥有经济学荣誉文学学士学位，并且是英国特许管理会计师协会的会员。
- Keeren Shah,has served as Chief Financial Officer since August 2020. Ms. Shah currently also serves as the Chief Operating and Financial Officer of Tiziana Life Sciences Limited, Accustem Sciences Inc and Actavia Lifesciences, Inc., having previously served as the Group Financial Controller for all businesses from June 2016 to July 2020. Prior to joining Okyo Pharma Limited , Ms. Shah spent 10 years at Visa, Inc. as a Senior Leader in its finance team where she was responsible for key financial controller activities, financial planning and analysis, and core processes as well as leading and participating in key transformation programs and Visa Inc.'s initial public offering. Before joining Visa, Ms. Shah also held a variety of finance positions at other leading companies including Arthur Andersen and BBC Worldwide. She holds a Bachelor of Arts with Honors in Economics and is a member of the Chartered Institute of Management Accountants.
- Robert J. Dempsey
Robert J. Dempsey，曾在Shire担任集团副总裁兼全球眼科主管，在被武田收购之前，他领导了Xiidra的剥离工作（lifitegrast眼科解决方案）5%，这是过去二十年中仅有的三笔预付款超过10亿美元的眼科交易之一。Xiidra的出售2019年向诺华支付的款项包括34亿美元的预付款和高达19亿美元的潜在里程碑付款。希德拉是首个获得FDA批准的针对干眼症体征和症状的疗法，并随后成为全球最畅销的品牌干眼症疗法之一。Dempsey先生设计并领导了Xiidra的成功发布并在眼表疾病适应症方面带来深厚的战略和商业专业知识，包括Restasis的直接管理责任和商业监督（环孢素眼用乳剂）0.05%。他在眼保健界的专业人脉广泛而成熟，反映出他作为CEO和独立董事在多家眼科公司的服务。
Robert J. Dempsey,previously served as Group Vice President and Head of Global Ophthalmology at Shire, prior to its acquisition by Takeda, where he led the divestiture of Xiidra (lifitegrast ophthalmic solution) 5%, which was one of only three ophthalmology deals in the past twenty years with more than $1 billion upfront. The sale of Xiidra to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments. Xiidra was the first FDA-approved therapy indicated for both the signs and symptoms of dry eye disease and went on to become one of the top-selling branded dry eye treatments globally. Mr. Dempsey architected and led the successful launch of Xiidra and has deep strategic and commercial expertise across ocular surface disease indications, including direct management responsibility and commercial oversight for Restasis (cyclosporine ophthalmic emulsion) 0.05%. His professional network in the eye care community is broad and well-established, reflecting his service as a CEO and independent director across multiple ophthalmic companies.- Robert J. Dempsey，曾在Shire担任集团副总裁兼全球眼科主管，在被武田收购之前，他领导了Xiidra的剥离工作（lifitegrast眼科解决方案）5%，这是过去二十年中仅有的三笔预付款超过10亿美元的眼科交易之一。Xiidra的出售2019年向诺华支付的款项包括34亿美元的预付款和高达19亿美元的潜在里程碑付款。希德拉是首个获得FDA批准的针对干眼症体征和症状的疗法，并随后成为全球最畅销的品牌干眼症疗法之一。Dempsey先生设计并领导了Xiidra的成功发布并在眼表疾病适应症方面带来深厚的战略和商业专业知识，包括Restasis的直接管理责任和商业监督（环孢素眼用乳剂）0.05%。他在眼保健界的专业人脉广泛而成熟，反映出他作为CEO和独立董事在多家眼科公司的服务。
- Robert J. Dempsey,previously served as Group Vice President and Head of Global Ophthalmology at Shire, prior to its acquisition by Takeda, where he led the divestiture of Xiidra (lifitegrast ophthalmic solution) 5%, which was one of only three ophthalmology deals in the past twenty years with more than $1 billion upfront. The sale of Xiidra to Novartis in 2019 included $3.4 billion upfront and up to an additional $1.9 billion in potential milestone payments. Xiidra was the first FDA-approved therapy indicated for both the signs and symptoms of dry eye disease and went on to become one of the top-selling branded dry eye treatments globally. Mr. Dempsey architected and led the successful launch of Xiidra and has deep strategic and commercial expertise across ocular surface disease indications, including direct management responsibility and commercial oversight for Restasis (cyclosporine ophthalmic emulsion) 0.05%. His professional network in the eye care community is broad and well-established, reflecting his service as a CEO and independent director across multiple ophthalmic companies.
- Gary S. Jacob
Gary S. Jacob，自2021年1月起担任Okyo Pharma Limited首席执行官兼董事。2018年11月至2020年3月，Jacob博士担任澳大利亚微生物组生物制药公司Immuron Limited的首席执行官。从2008年7月到2017年12月，Jacob博士担任生物制药公司Synergy Pharmaceuticals Inc.的总裁兼首席执行官，并于2008年7月至2018年11月担任多个职位，并于2013年9月至2018年11月担任Synergy Pharmaceuticals Inc.的董事长。2018年12月12日，Synergy Pharmaceuticals Inc.根据美国《破产法》第11章提交了一份救济申请。自2014年3月19日起，Jacob博士一直担任生物技术公司Hepion Pharmaceuticals, Inc.的董事会主席，更早前于2013年5月15日至2014年3月19日担任首席执行官。Jacob博士于2003年5月至2013年1月期间担任Callisto Pharmaceuticals，Inc.的首席执行官，并于2004年10月至2013年1月期间担任董事。Jacob博士还担任Rasna Therapeutics，Inc.的董事，并且是Cardiff Oncology, Inc.的前任董事。Jacob博士在制药和生物技术行业拥有超过35年的经验，跨越多个学科，包括研发、运营和业务发展。在1999年之前，Jacob博士曾担任Monsanto科学研究员，专门研究糖生物学领域。1997年至1998年，Jacob博士在Monsanto公司担任企业科学与技术部门功能基因组学主任。Jacob博士还曾于1990年至1997年担任G.D. Searle Pharmaceuticals Inc的糖生物学总监。在1986年至1990年期间，他担任英国牛津大学G.D. Searle糖生物学小组的经理。
Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. From March 19, 2014 until February 2024, Dr. Jacob was the Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Actavia Lifesciences, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.- Gary S. Jacob，自2021年1月起担任Okyo Pharma Limited首席执行官兼董事。2018年11月至2020年3月，Jacob博士担任澳大利亚微生物组生物制药公司Immuron Limited的首席执行官。从2008年7月到2017年12月，Jacob博士担任生物制药公司Synergy Pharmaceuticals Inc.的总裁兼首席执行官，并于2008年7月至2018年11月担任多个职位，并于2013年9月至2018年11月担任Synergy Pharmaceuticals Inc.的董事长。2018年12月12日，Synergy Pharmaceuticals Inc.根据美国《破产法》第11章提交了一份救济申请。自2014年3月19日起，Jacob博士一直担任生物技术公司Hepion Pharmaceuticals, Inc.的董事会主席，更早前于2013年5月15日至2014年3月19日担任首席执行官。Jacob博士于2003年5月至2013年1月期间担任Callisto Pharmaceuticals，Inc.的首席执行官，并于2004年10月至2013年1月期间担任董事。Jacob博士还担任Rasna Therapeutics，Inc.的董事，并且是Cardiff Oncology, Inc.的前任董事。Jacob博士在制药和生物技术行业拥有超过35年的经验，跨越多个学科，包括研发、运营和业务发展。在1999年之前，Jacob博士曾担任Monsanto科学研究员，专门研究糖生物学领域。1997年至1998年，Jacob博士在Monsanto公司担任企业科学与技术部门功能基因组学主任。Jacob博士还曾于1990年至1997年担任G.D. Searle Pharmaceuticals Inc的糖生物学总监。在1986年至1990年期间，他担任英国牛津大学G.D. Searle糖生物学小组的经理。
- Gary S. Jacob,has served as Chief Executive Officer and a director of Okyo Pharma Limited since January 2021. From November 2018 to March 2020, Dr. Jacob was the Chief Executive Officer of Immuron Limited, an Australian microbiome biopharmaceutical company. From July 2008 until December 2017, Dr. Jacob was President and Chief Executive Officer of Synergy Pharmaceuticals Inc., a biopharmaceutical company, where he held various positions from July 2008 to November 2018 and he served as its Chairman from September 2013 to November 2018. On December 12, 2018, Synergy Pharmaceuticals Inc. filed a petition for relief under Chapter 11 of the U.S. Bankruptcy Code. From March 19, 2014 until February 2024, Dr. Jacob was the Chairman of the Board of Hepion Pharmaceuticals, Inc., a biotechnology company, and earlier served as its Chief Executive Officer from May 15, 2013 until March 19, 2014. Dr. Jacob served as Chief Executive Officer of Callisto Pharmaceuticals, Inc. from May 2003 until January 2013 and a director from October 2004 until January 2013. Dr. Jacob also serves as a director of Actavia Lifesciences, Inc., and is a past director of Cardiff Oncology, Inc. Dr. Jacob has over 35 years of experience in the pharmaceutical and biotechnology industries across multiple disciplines including research & development, operations and business development. Prior to 1999, Dr. Jacob served as a Monsanto Science Fellow, specializing in the field of glycobiology, and from 1997 to 1998 Dr. Jacob was Director of Functional Genomics, Corporate Science & Technology, at Monsanto Company. Dr. Jacob also served from 1990 to 1997 as Director of Glycobiology at G.D. Searle Pharmaceuticals Inc. During the period of 1986 to 1990, he was Manager of the G.D. Searle Glycobiology Group at Oxford University, England.